Replies to post #20526 on ViaDerma Inc (VDRM)

[Mistral]

KEOUGH V. OTIKO ET AL - READ BELOW

Complaint, Jurisdiction, Statement of Claim, Irreparable Injury, Relief

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130656929

Case Summary and Detailed Discussion

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130651594

Breach of Contracts and Unauthorized Disclosure and Use of Trade Secrets

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130654231

Steven J. Keough Bio is below. Today he is President and CEO of Kasten BioPharma OTC:PK KAST. Kasten merged with Keough's business Dakota Life Sciences in March 2017. They are bringing competitive, and likely superior, products to market from their new fulfillment center in Bridgeport, CT.

http://dakotalifesci.com

Mr. Keough is a graduate of Boston College Law School (J.D.), the Catholic University of America in Washington, D.C. (M.A. in Congressional Studies), and the United States Naval Academy at Annapolis (B.S.). His technology area of physics and his background as a submarine officer enable him to navigate comfortably in most technology fields, including medical devices and related sciences, manufacturing, optics, computer science, chemical coatings, formulations, and numerous others.

In the late 1980s, Mr. Keough was responsible for the patent accounts of numerous Asia-based manufacturing giants. He then went on to become widely known in the 1990s as an international expert on the phenomenon known as patent flooding. Mr. Keough played a pivotal role in the corporate-legal relationship of the mid-2000s which led to the largest medical device product release in history. This involved the first drug eluting cardiac stent to reach the United States market. From 2004-2008, Mr. Keough was Chief Patent Counsel at a public company, and contributed to the rapid rise of that company's market valution during his tenure.

With decades of experience in private practice and corporate settings, Mr. Keough has great insight into product life cycles and strategies of protection. He received a certificate in Finance for Non-Financial Executives from the Graduate School of the University of Chicago, and is quite aware of the financial pressures on corporate budgets. This awareness is at the heart of his founding of Law Offices National, P.A., to provide highly focused and efficient service in the patent arena- which has been a very costly area of patent expense to most businesses.

As a naval officer, Mr. Keough specialized in missile technology. He also commanded numerous U. S. naval forces in virtually all of the geographic regions of the world- retiring in 2004 at the naval rank of Captain. Mr. Keough also served as a Congressionally appointed civilian panel member charged with overseeing the conduct of the U.S. Department of Defense Threat Reduction Agency in the late 1990s and early 2000s. His area of responsibility related specifically to mitigating threats against the country from nuclear devices.

If he abandoned the patent and the Dr. Filed a new patent to protect it where is the issue?

[GreenBrickRoad]

Otiko was hired on as a consultant, correct? If he was an equal partner in this process, he might have a claim worthy of some consideration in court. But, if he was contracted or temporarily employed to do a job, which is my understanding, it's a completely different story. He probably would have signed an agreement forfeiting any legal claims to the work he, Keough, Phillips, et al collaborated on.

In that event, it doesn't matter if the patent was previously "abandoned." Otiko traded his expertise and time for money. If he was in fact paid, and assuming the terms of his contract were not riddled with negligence, it doesn't matter if the patent associated with his work was abandoned or not. He would have no legal claim to it.